BioCentury | Aug 29, 2017
Distillery Therapeutics

Cancer

...the oligo. TARGET/MARKER/PATHWAY: VE-cadherin (CD144; cadherin-5); microRNA-27a (miR-27a) LICENSING STATUS: Patented by Centenary Institute and Mirrx Therapeutics A/S...
BioCentury | Oct 17, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

...in other arterial injury models and determining the therapeutic window for use of the antagomir. Mirrx Therapeutics A/S...
BioCentury | Feb 8, 2010
Financial News

Mirrx Therapeutics completes venture financing

Mirrx Therapeutics A/S , Lyngby, Denmark Business: Supply/Service Date completed: 2/4/10 Type: Venture financing Raised: Undisclosed Investors: Seed Capital; Inventure Capital; Vecata WIR Staff...
Items per page:
1 - 3 of 3
BioCentury | Aug 29, 2017
Distillery Therapeutics

Cancer

...the oligo. TARGET/MARKER/PATHWAY: VE-cadherin (CD144; cadherin-5); microRNA-27a (miR-27a) LICENSING STATUS: Patented by Centenary Institute and Mirrx Therapeutics A/S...
BioCentury | Oct 17, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

...in other arterial injury models and determining the therapeutic window for use of the antagomir. Mirrx Therapeutics A/S...
BioCentury | Feb 8, 2010
Financial News

Mirrx Therapeutics completes venture financing

Mirrx Therapeutics A/S , Lyngby, Denmark Business: Supply/Service Date completed: 2/4/10 Type: Venture financing Raised: Undisclosed Investors: Seed Capital; Inventure Capital; Vecata WIR Staff...
Items per page:
1 - 3 of 3